Article

invezz.com on 2021-10-14 00:21

ROTH initiates Flora Growth at ‘buy’: shares could nearly double

CRISPR reported updated data for phase 1 trial of CTX 110. RBC Capital maintained a "sector perform" rating on CSPR with an unchanged PT of $117.

Related news